QMS in Pharmaceutical Industry…
ICH Q12 – Lifecycle Management (2019
This provides a framework for managing post-approval changes throughout a drug’s lifecycle. It aims to:
-Enhance regulatory flexibility by distinguishing between changes that require approval vs. those that can be managed within the company’s Pharmaceutical Quality System (PQS).
-Introduce established conditions (ECs) to define critical quality attributes and parameters that require regulatory oversight.
-Support continual improvement by reducing the regulatory burden for well-managed changes.
ICH Q13 provides guidelines for implementing continuous manufacturing (CM) in the pharmaceutical industry, covering:
-Scientific and regulatory considerations for small and large molecules.
-Process control strategies and real-time monitoring to ensure product quality.
-Harmonization of global regulations to support CM adoption.
Both guidelines contribute to a more efficient, science-based regulatory approach, allowing innovation while ensuring product quality and patient safety.
ICH Q12 Implementation: Lifecycle Management
1. Established Conditions (ECs)
Defines critical elements of a manufacturing process that require regulatory approval if changed.
Non-ECs can be adjusted within the Pharmaceutical Quality System (PQS) without regulatory approval.
2. Product Lifecycle Management (PLCM) Document
Provides a structured way to present post-approval changes to regulators.
Helps streamline regulatory submissions across different regions.
3. Categorization of Post-Approval Changes
Low-risk changes (e.g., minor equipment upgrades) can be managed within PQS.
Moderate-to-high risk changes require regulatory submission but may follow a streamlined process if ICH Q12 is adopted.
Regulatory Impact of ICH Q12
✅ Reduced regulatory burden for minor post-approval changes.
✅ Greater global harmonization, reducing redundant submissions.
✅ Encourages innovation by allowing manufacturers to implement improvements faster.
ICH Q13 Implementation: Continuous Manufacturing (CM)
1. Process Control Strategies
Real-time monitoring (e.g., PAT tools) ensures consistent product quality.
Automated feedback loops adjust parameters to maintain quality.
2. Regulatory Considerations
Companies must demonstrate control over variability in raw materials and process conditions.
Emphasis on real-time release testing (RTRT) instead of traditional batch testing.
Regulatory Impact of ICH Q13
✅ Faster and more flexible manufacturing with fewer disruptions.
✅ Better quality assurance through continuous monitoring.
✅ Alignment of global regulatory expectations to support CM adoption.
-> Challenges in Implementation
🔹 Regulatory Adoption Variability – Not all regions fully align with ICH Q12/Q13 yet.
🔹 Investment Costs – Continuous manufacturing requires high initial investment.
🔹 Technical Expertise – Companies need advanced process control and digital infrastructure.
